@jenweiying

🇸🇬 Haematologist & leukemia physician at @MDAndersonNews and @NCIS_NUHS. I’m dark blue 🚣‍♀️ @UniofOxford! Trainees: https://nitter.cf/t.co/aJvbqY1h03 - Haem made simple!

 Singapore
learnhaem.com
Joined October 2011
  • Tweets1.3K
  • Following281
  • Followers499
40Media
Don’t miss this. It’s the best flow training!
Sa A Wang, MD@SaWangMD
Aug 19
Registration for the MD Anderson Integration of Flow Cytometry in Hematopathology course closes at the end of August! Join us in person or virtually. Trainee registration is only $100. In-person participants are also invited to dinner banquet. Scan the QR code for registration.
1
4
19
3,911
Huge congrats to @doctorpemm for an outstanding DoCM GR this AM @UTMDAnderson on his remarkable journey in the fight against #BPDCN. From putting this rare disease on the 🗺️ getting 2 @FDAOncology approvals establishing @NCCN guidelines & brining together an entire community of physicians and scientists to concur this disease. Inspirational!! 👏🏼
4
16
1
61
4,858
Excited and proud to share our special issue on #Leukemia that @ljmedeirosMD & I put together for @Human_Pathology We brought together incredible experts to write about the latest in the field. 13 articles, each one #hemepath GOLD💎! 1/14🧵 Starting with our intro to the issue sciencedirect.com/science/ar…
11
40
7
127
17,972
Advanced fellowship in leukemia @DanaFarber for 2027-2028, application is open. jobcenter.hematology.org/job…
15
30
3,398
Agree. @ASH_hematology we ❤️ you, but it took an hour per abstract - and a fee increase to $95 for the pleasure! Not to mention constantly increasing costs of attending. These are real barriers to participating in #ASH26, please do better for hematology. 🙋‍♀️ I volunteer to help!
Sanam Loghavi, MD صنم لغوی 🔬🧬
@sanamloghavi
Aug 2
⏰ for my annual rant 😖 on just how clunky & inefficient #ASH26 abstract submission portal is. even worse than last year. Dear @ASH_hematology I know U care b/c I see how hard U all work But I think U don’t realize just how awful the end user experience is. 1.5 hrs for 1 abstract. 👇🏼UNACCEPTABLE . 🤯 Change your vendor, use AI tools, & PLEASE DO BETTER. 🙏🏻
10
2,127
Look at these beauties lining up and posing for my camera Monoblast ➡️promonocyte ➡️ mature monocyte.   With all the hype about #RAS I think they know the hemepath paparazzi is hunting for them 📸
5
43
1
148
5,825
👏👏👏Wonderful Leukemia Faculty Dinner 🥘 this evening hosted by Dr @GBorthakur & Dr @garciamanero ! Greatest team to work with ! #leusm #MPNSM #BPDCN #MDSsm #CMMLsm #endcancer 🙌 | @jenweiying
3
3
51
1,657
👉👉👉Breaking News 📰 | Proud to share the wonderful news for our patients & families facing #BPDCN of @US_FDA @FDAOncology approval for #Pivekimab #CD123 for our patients with #BPDCN !🙏| led by @doctorpemm & @Daver_Leukemia | @UTMDAnderson #endcancer fda.gov/drugs/resources-info…
21
41
4
139
25,983
Thank you @doctorpemm for your support! Had the opportunity to work with the pioneers and leaders of the FLT3, IDH & menin triplet fields. We review data, choice of agents & dose adjustments for myelosuppression / specific toxicities. Hope it’s helpful! @NicholasShortMD
Naveen Pemmaraju, MD@doctorpemm
Mar 12
👉Excellent review article led by Dr .@jenweiying & Dr DiNardo on Optimizing lower intensity triplet tx in AML-a practical guide | @CLachowiez @jaltmanmd @MusaYilmazMD @yasminabaza1 @Daver_Leukemia @GhayasIssa @LeukDocJZ | #BCJ #BloodCancerJournal #leusm nature.com/articles/s41408-0…

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

Blood Cancer Journal - Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

nature.com
2
25
2,988
👉👉👉Lovely team moment together with Leukemia team + Associate Heme/Onc Fellowship PD , Dr Amishi Shah ! #leusm #meded #endcancer #MPNSM #BPDCN 🙌
1
1
27
1,269
👉👉👉#FollowFriday | Shout out & pls make sure to follow Dr Sanam Loghavi .@sanamloghavi our superstar brilliant world-class #hematopathologist ! An amazing teacher/doctor/researcher & amazing human being ! #leusm #BPDCN #MPNSM #RareDisease @HemeReports faculty.mdanderson.org/profi…
6
6
69
4,522
👉👉👉MPN & AML teams meeting up together to brainstorm new ideas 💡 & new collaborations for 2026 !! #endcancer #MPNSM ##leusm |||| @Daver_Leukemia @mkonople @DanielleHammo20 @HannahGoulart @HusseinAbbasLab @JAK2TheFuture
2
3
40
1,721
A privilege to be part of this important guideline recommendation about how to optimize frontline triplet regimens in AML w/ a stellar group of colleagues 👇@Daver_Leukemia @jaltmanmd @CLachowiez @JenMarvinPeek @UNC_Lineberger
Blood Cancer Journal@BloodCancerJnl
25 Nov 2025
Excellent Current Treatment Algorithm article. Open access! Optimizing lower intensity triplet therapy in acute myeloid leukemia. nature.com/articles/s41408-0…

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

Blood Cancer Journal - Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide

nature.com
2
5
1
26
5,631
I enjoyed this review by Drs Jen and DiNardo on triplets in AML pubmed.ncbi.nlm.nih.gov/4129… @courtney

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide - PubMed

Venetoclax-based doublets with azacitidine or low dose cytarabine are the standard of care for the treatment of acute myeloid leukemia (AML) in older patients or those unfit for intensive chemother...

pubmed.ncbi.nlm.nih.gov
8
1
33
3,480
Not all menin inhibitors are the same! Incredible presentation by @Daver_Leukemia- updated results of Enzomenib Mono Tx for R/R NPM1m & KMT2Ar AML. ORR >70% & CR/CRh >40% in KMT2Ar AML with median DOR >12 mos. Privilege to be part of the Enzo dev. In AML @UNC_Lineberger #ASH2025
2
11
55
3,009
ICYMI: @jenweiying breaks down her #ASH25 presentation of results from a phase II study of the all-oral combination of revumenib with decitabine/cedazuridine and venetoclax in newly diagnosed AML. #EndCancer
Tapan Kadia@TapKadia
6 Dec 2025
Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews
5
23
3,871
Wei Ying Jen retweeted
OncLive.com
@OncLive
7 Dec 2025
WATCH: Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML. @jenweiying @MDAndersonNews @ASH_hematology #ASH25 #leusm #Hematology onclive.com/view/dr-jen-on-t…

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML | OncLive

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

onclive.com
1
3
616
Totally agree! Having time (well, at the expense of sleep 😂) to sit and talk and just have fun makes all the difference. Thank you for the delicious Indian food! ❤️
Nitin Jain@NitinJainMD
9 Dec 2025
Best part of ASH is meeting colleagues Here with my wonderful leukemia colleagues enjoying some late night yummy Indian food @jenweiying Missed @Anand_88_Patel for the pic
1
16
1,454
Wei Ying Jen retweeted
Fieke Hoff@FiekeHoff
8 Dec 2025
Amazing work & excellent presentation, congrats @jenweiying and the rest of the team!
Tapan Kadia@TapKadia
6 Dec 2025
Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews
1
1
8
1,390
Kudos @Daver_Leukemia and @NicholasShortMD on not just your beautiful work but your outstanding mentorship of Dr. Azevedo! Outstanding long term follow up for aza ven gilt for adults w FLT3m AML inappropriate IC. #ASH25 #ASHScavengerHunt
3
13
1
43
3,956
Load more